Carregant...
From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management.
Interleukin(IL)-17 inhibitors display higher efficacy than both TNFi and IL-12/23i, which increased the goal psoriasis area severity index (PASI) from 75 to PASI 90 or even PASI 100. Ixekizumab, a recombinant, humanized IgG4 monoclonal antibody targeting IL-17A displayed a high efficacy and safety i...
Guardat en:
| Publicat a: | Dermatol Ther |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6579640/ https://ncbi.nlm.nih.gov/pubmed/30942952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.12886 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|